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their uninsured status. The current study aimed to evaluate the effect of new
health system from the perspective of the insured students one year after program
implementation. METHODS: Based on the Chinese Customer Satisfaction Index
and review of the literatures, we built a satisfaction evaluation system for URMS of
university students, with one first-level, 7 second-level (Latent variable, xm) and 24
third-level indicators (Explicit variable, yn) to be scored on a five-point Likert-type
scale. After pilot testing and subsequent adjustment, 400 questionnaires were is-
sued to students in 4 universities in NE China. After obtaining the affecting order of
third indexes to their corresponding secondary index through the correlation test,
a Structural Equation Model (SEM) for the satisfaction assessment of URSM was
built basing on the calculated Path coefficient between the xm and yn after multi-
ple linear regressions. Goodness of fit statistics of SEM were used to assess the
match between this model and satisfaction assessment. RESULTS: A total of 393
questionnaires were returned giving a recovered rate 98.3%. The path coefficients
between xm and ynwere: customer trust 1.26, the perceived quality 0.88, customer
complaints 0.80, customer expectations 0.44, public information 0.31, and image of
the government 0.29. The satisfaction score of UMRS (29.06 out of 69.75 points)
showed very low satisfaction level of university students towards the program.
CONCLUSIONS: The results showed the satisfaction assessment model was suit-
able to this study. Based on the order of path coefficients, several reform proposals
for improving university students’ medical insurance are proposed, including es-
tablishing a multi-level medical insurance system with corresponding regulatory
and monitoring mechanism of its performance; as well as enhancing awareness
and education of students about health insurance.
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OBJECTIVES: To determine the level of availability and transparency of the drug
provision system of Kazakhstani populationat the expense of the governmental
budget and to detect the level of their satisfaction. METHODS: A total of 1236
patients filled the random anonymous questionnaire in polyclinics and hospitals
in Almaty, East-Kazakhstani, Kzyl-Orda and Karaganda regions. The questionnaire
consisted of 38 questions. RESULTS: A total of 51.6 % of the patients were provided
with drugs by the reduced price with the substitution coefficient of 0,5. Almost 47%
of the patients were refused to be provided with medical assistance and drugs
within the scope of the extent of the free guaranteed medical assistance; further-
more, 80,3% of the asked had to use additional amount of their ownmoney during
not only at the ambulatory but also at the hospital level. At the same time, it was
unaffordable for 63,8% of the asked to buy drugs. A total of 57,9% of the patients
defined the drug availability provided within the scope of the guaranteed free
medical assistance as poor and unsatisfactory. Moreover, 76,8 % claimed that sev-
eral medicines were absent in the current and last year lists. In order to protect
their rights, the patients applied to medical organizations (27,9 %), to local public
health services (21,9 %), to social patients protecting services (11,1 %), to courts (4,3
%) and others (17,1 %). In 43,7% of cases doctors either had not explained their
prescription or rarely -17,3 %. 42 % were dissatisfied with their doctors; moreover,
71,5%of the patients suggested that educational brochures containing information
on the disease, side effects of the prescribed medicines, etc. should be provided.
CONCLUSIONS: Therefore, there are problems with the drug provision within the
scope of the guaranteedmedical assistance whichmainly concernwith poor avail-
ability of medicines and low compliance.
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OBJECTIVES: Teething is a natural occurrence of childhood, yet there is no consen-
sus regarding what symptoms are associated with teething and whether medical
treatment relieves these symptoms. The objective of this study was to assess what
symptoms parents ascribed to their child’s teething and how satisfied they were
with the how their paediatrician managed the teething with existing medicines.
METHODS: We conducted a prospective observational study where a randomly
selected 500 French pediatricians were asked to fill out case reports of the first four
3 to 24 month old patients they treated for teething. Of these, 161 agreed to partic-
ipate and filled out case reports of medical and treatment data for 597 children at
baseline. A total of 412 parents filled out a satisfaction questionnaire and a 7-day
diary assessing teething symptoms and severity. RESULTS: The median age was 8
months, 58.5%weremale and for 49.8% of them itwas the first teething experience.
At baseline, the average number of symptoms parents ascribed to teethingwas 5.1,
with the main symptoms including gums tumefaction (80.5%), sialorrhea (70.3%),
and unusual agitation/irritability (67.1%). Seven days after a treatment was pre-
scribed, the percent of children displaying these same symptomsdropped to 59.6%,
49.6%, and 31.7%, respectively. Overall, 85.7% of parents indicated that they give
their child medication for teething, 80.7% of the parents were “satisfied” or “very
satisfied” with the treatments prescribed and 83.2% were willing to use it for a
future tooth eruption of their child. Satisfaction did not differ by treatment.
CONCLUSIONS: The results of this study show a good parents’ global satisfaction
regarding teething symptoms evolution over the time. Regardless of the treatment
prescribed or whether they followed the prescribed treatment, the overall teething
management by the paediatricians satisfied them.
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OBJECTIVES: Patients’ perceptions of products used for testosterone replacement
therapy (TRT) may vary according to product attributes such as application site,
duration of use and physical qualities. The objective of this study was to assess the
domains associated with the preference for TRT products, to identify salient
themes and attributes, and to develop a patient-reported outcomes (PRO) instru-
ment for use in clinical trials. METHODS: The study used a standard qualitative
approach to develop a theoretical framework and to identify items and develop
themes from a set of attributes associated with TRT product use and preference.
Items and themes gleaned froma literature review and expert opinionwere used to
develop a theoretical framework and a discussion guide. This guide was used by
trained researchers to interview patients, who were experienced using TRT and
voluntarily agreed and consented to participate in the research study using IRB-
approved documents. Results from telephone interviews were transcribed using
NVivo 9 qualitative analysis software (QSR International, Cambridge, MA) and clas-
sified according to TRT themes. Demographic and other data collected through the
interview process were entered into a spreadsheet for descriptive analysis.
RESULTS: The saturation of items and exhaustion of themes was accomplished by
58 male patients with an average age of 55.01.3 years (22-69). Patients used TRT
for an average of 18340.5 days, with approximately 50% of patients having expe-
rience with more than one form of TRT. Five patients participated in cognitive
debriefing. The study revealed 8 themes: ease of use, libido, preference, product
characteristics, physiological impact, psychological impact, side effects, and treat-
ment experience. CONCLUSIONS: Themes and items related to TRT use were in
concordance with the theoretical framework developed in the study. The PRO in-
strument can be further developed for potential use in clinical trials.
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OBJECTIVES: The purpose of this research was to determine the impact of patient-
reported outcome (PRO) endpoint type (primary vs. nonprimary) on PRO-based
labeling claims. This review examines PROs as both primary and nonprimary end-
points used to demonstrate treatment benefit of new molecular entities (NMEs)
and biologic license applications (BLAs) in the United States (US) in the years
2000-2010.METHODS: Food and Drug Administration (FDA) Drug Approval Reports
were reviewed to identify all approved NMEs and BLAs between January 2000 and
December 2010. Generic products with tentative approvals were excluded. For all
identified products with publically available drug approval packages, the medical
review sections were reviewed to identify PRO endpoint use. Product label indica-
tion and clinical trials sectionswere reviewed to determine the number and type of
PRO claims. RESULTS:A total of 264 NMEs/BLAswere identified. Of these, 63 NMEs/
BLAs (24%) were granted PRO-based claims. The majority of product claims were
for disease- or condition-specific signs and symptoms. Of the 63 products with
PRO-based claims, the PRO was the primary endpoint for 54 (86%). All 54 PRO
primary endpoints were sign and symptom evaluations; of these, 3 included a
functioning measure as a coprimary endpoint. CONCLUSIONS: Successful PRO
label claims are typically based on primary endpoints assessing signs and symp-
toms. Based on this research, studies with PROs dedicated as primary endpoints,
compared with nonprimary, are more likely to facilitate positive regulatory review
and acceptance of PROs in support of label claims.
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OBJECTIVES: Physical function limitation and muscle wasting are commonly as-
sociated withmany chronic conditions and the aging process. The National Health
andNutrition Examination Survey (NHANES) 2001-2002 include a physical function
limitation questionnaire, as well as examinations measuring muscle mass and
muscle strength. The factor structure of the physical function limitation question-
naire, however, is unknown. The aim of this study was to evaluate the factor
structure of this questionnaire, and to examine the relationship between physical
function andmusclemeasurements in the elderly in the United States.METHODS:
Data from NHANES 2001-2002 participants aged 60-80 years (n1394) was used for
this study. First, a maximum likelihood based exploratory factor analysis (EFA)
with Geomin rotation (an oblique rotation) of the nineteen physical function limi-
tation items was implemented. The relationship among the identified question-
naire domains, muscle strength (as measured by isokinetic strength of the knee
extensors), and muscle mass (as measured by appendicular skeleton muscle mass
index) were examined using partial correlation coefficient (PCC) adjusted for age,
gender, and percentage of body fat. RESULTS: The EFA produced a 3-factor solution
for items measuring gross motor function, fine motor function, and social and
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